Profile data is unavailable for this security.
About the company
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
- Revenue in EUR (TTM)0.00
- Net income in EUR-14.76m
- Incorporated2006
- Employees19.00
- LocationGeneuro SA3, Chemin du Pre-FleuriPLAN-LES-OUATES 1228SwitzerlandCHE
- Phone+41 225524800
- Fax+41 227945086
- Websitehttps://www.geneuro.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Oxurion NV | 2.00k | 1.96m | 490.69k | 11.00 | 0.0114 | -- | 0.2421 | 245.34 | 0.6137 | 0.6137 | 0.0006 | -3.76 | 0.0004 | -- | 0.0015 | 181.82 | 41.10 | -101.52 | -- | -249.96 | -650.00 | 53.85 | 97,950.00 | -2,672.68 | -- | -- | -- | -- | -98.86 | -76.22 | 100.63 | -- | -- | -- |
| PCI Biotech Holding ASA | 405.71k | -1.78m | 597.61k | 7.00 | -- | 0.5518 | -- | 1.47 | -0.5502 | -0.5502 | 0.1256 | 0.3353 | 0.1676 | -- | 0.896 | 669,714.30 | -73.44 | -41.44 | -92.22 | -46.61 | -- | -- | -438.10 | -897.91 | -- | -- | 0.022 | -- | 125.25 | -6.43 | 19.19 | -- | -- | -- |
| Lidds AB | 0.00 | -522.69k | 639.48k | 1.00 | -- | 4.57 | -- | -- | -0.0409 | -0.0409 | 0.00 | 0.0109 | 0.00 | -- | -- | 0.00 | -99.68 | -64.76 | -119.64 | -76.72 | -- | -1,554.86 | -- | -2,637.08 | -- | -- | 0.00 | -- | -- | -- | 85.23 | -- | -65.39 | -- |
| Epigenomics AG | 4.00k | -2.76m | 762.95k | 3.00 | -- | -- | -- | 190.74 | -3.14 | -3.14 | 0.0046 | 0.00 | 0.0003 | -- | -- | 2,000.00 | -23.10 | -55.09 | -23.17 | -61.61 | -2,300.00 | -0.2095 | -69,025.00 | -473.65 | -- | -- | 1.00 | -- | -100.00 | -- | 24.90 | -- | -- | -- |
| MediGene AG | -100.00bn | -100.00bn | 824.77k | 87.00 | -- | 0.0415 | -- | -- | -- | -- | -- | 1.33 | -- | -- | -- | -- | -- | -22.31 | -- | -25.28 | -- | 90.15 | -- | -123.17 | -- | -- | 0.1146 | -- | -80.69 | -4.89 | -94.20 | -- | -8.12 | -- |
| GeNeuro SA | 0.00 | -14.76m | 916.64k | 19.00 | -- | -- | -- | -- | -0.594 | -0.594 | 0.00 | -0.5548 | 0.00 | -- | -- | 0.00 | -165.51 | -96.43 | -356.72 | -185.61 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -20.96 | -- | -20.13 | -- |
| Shortwave Life Sciences PLC | 52.50k | -295.21k | 997.28k | 2.00 | -- | 0.2391 | -- | 19.00 | -0.007 | -0.007 | 0.0012 | 0.0669 | 0.0155 | -- | 2.26 | 22,850.00 | -8.73 | -- | -9.00 | -- | 99.34 | -- | -562.34 | -- | -- | -- | 0.00 | -- | -19.39 | -- | 76.00 | -- | -- | -- |
| IntegraGen SA | 6.69m | -1.55m | 1.02m | 39.00 | -- | 2.88 | -- | 0.1523 | -0.2338 | -0.2338 | 1.01 | 0.0526 | 1.36 | 8.98 | 4.92 | 171,592.60 | -31.48 | -1.90 | -115.71 | -4.51 | 59.50 | 64.12 | -23.12 | -1.44 | 0.9581 | -- | 0.5447 | -- | -30.62 | 0.9904 | -49.22 | -- | -- | -- |
| Fluicell AB | 251.27k | -924.00k | 1.02m | 11.00 | -- | 1.01 | -- | 4.07 | -7.18 | -7.18 | 1.95 | 7.86 | 0.1257 | -2.79 | 3.22 | 268,100.00 | -46.21 | -89.03 | -62.52 | -133.15 | 428.87 | 86.83 | -367.74 | -656.39 | 0.6057 | -- | 0.00 | -- | -44.31 | -5.66 | 41.59 | -- | 33.86 | -- |
| Stayble Therapeutics AB | 0.00 | -788.83k | 1.09m | 2.00 | -- | 1.38 | -- | -- | -0.168 | -0.168 | 0.00 | 0.1314 | 0.00 | -- | -- | 0.00 | -78.98 | -78.82 | -83.99 | -92.78 | -- | -- | -- | -- | -- | -- | 0.0913 | -- | -- | -- | 47.69 | -- | -- | -- |
| Paion AG | -100.00bn | -100.00bn | 1.14m | 64.00 | -- | -- | -- | -- | -- | -- | -- | -0.4074 | -- | -- | -- | -- | -- | -24.86 | -- | -34.32 | -- | -- | -- | -52.40 | 0.5078 | -- | 1.17 | -- | 366.42 | 41.74 | 97.34 | -- | 129.37 | -- |
| Novakand Pharma AB | 0.00 | -4.86m | 1.18m | 5.00 | -- | 0.6304 | -- | -- | -0.4283 | -0.4283 | 0.00 | 0.1653 | 0.00 | -- | -- | 0.00 | -103.07 | -54.11 | -112.87 | -63.47 | -- | 70.00 | -- | -275,694.40 | -- | -- | 0.00 | -- | -- | -- | 31.32 | -- | -- | -- |
| Respiratorius AB (publ) | 0.00 | -667.74k | 1.19m | -- | -- | 0.3941 | -- | -- | -1.30 | -1.30 | 0.00 | 4.09 | 0.00 | -- | -- | -- | -21.57 | -- | -22.10 | -- | -- | -- | -- | -- | -- | -133.51 | 0.00 | -- | -- | -- | 3.36 | -- | -32.52 | -- |
Data as of Jan 22 2026. Currency figures normalised to Geneuro SA's reporting currency: Euro EUR
0.96%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Montpensier Arbevel SASas of 31 Dec 2024 | 200.00k | 0.67% |
| Clay Asset Management SASas of 30 Jun 2025 | 85.92k | 0.29% |
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
